Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 6 Gynecologic 6 Gastrointestinal 5 Breast 3 Tumor-Agnostic 2 Thoracic 2 Sarcoma 2 Plasma cell 1 Genitourinary 1 Endocrine 1 Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 124 daratumumab 73 Lenalidomide 72 Bortezomib 61 pomalidomide 45 Cyclophosphamide 41 carfilzomib 40 Calcium Dobesilate 36 Specimen Handling 34 Biopsy 30 Magnetic Resonance Spectroscopy 27 belantamab mafodotin 24 isatuximab 20 fludarabine 20 dexamethasone acetate 18 dexamethasone 21-phosphate 18 auricularum 18 Melphalan 18 talquetamab 16 iberdomide 16 fludarabine phosphate 12 selinexor 11 elotuzumab 10 X-Rays 10 tocilizumab 9 Nivolumab 8 Sirolimus 7 Crizotinib 7 trametinib 6 Whole-Body Irradiation 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

dostarlimab × Plasma cell × 90 days × Clear all

NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting

208 enrolled 5 charts

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡